Biovie Inc. · NASDAQ:BIVI
Biovie — Technical Presentation (August 2023)
8 slides from Biovie's technical presentation, Aug 27, 2023
Slide 1: Effects of NE3107 Anti-inflammatory Treatment in a Marmoset Model of Parkinson's Disease
Effects of NE3107 Anti- inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s Disease in a Marmoset Monkey Model Ingrid H.C.H.M. Philippens1, Clarence Ahlem2, Christopher L. Reading2 1Charles River Nederland B.V., Beerse, Antwerp, Belgium; 2BioVie Inc., Carson City,
Slide 2: Background
Background Neuroinflammation • Oral • BBB-permeable Insulin resistance NE3107 • Small molecule • Anti-inflammatory • Insulin-sensitizing • Associated with Neurodegeneration increased brain glutathione • Favorable safety ROS profile For more information see Athauda D, Foltynie T, 20161; and Dias V, J
Slide 3: Study design
Study design Week Marmoset N=18 5 MPTP-induceda Parkinson’s-like disease Randomized 1:1:1 8 Amantadine HCl NE3107 Vehicle control 1 mg/kg/day 30 mg/kg/day Daily efficacy assessments (monotherapy; immobility scores) 10 Levodopa (5-25 mg/kg/day) Daily efficacy assessments (combination therapy; immobil
Slide 4: Results
Results A Mean immobility scores with monotherapy B Mean immobility scores with combination therapy 4 Mean immobility score 3.00 *† 3 2.71 2.59 2.72 2.74 *† 2.8 2.72 *† * *‡ *‡§ *‡§ 2.26 2.10 *‡§ 2 1 0 Week 7 Week 8 Week 9 Vehicle Amantadine HCl NE3107 *P<0.01 vs vehicle; †P<0.01 vs amantadine HCl m
Slide 5: Conclusions
Conclusions NE3107 may influence neuro-motor signaling and neurodegeneration by modulating neuroinflammation Improved Observed effects of NE3107 Improved mobility with levodopa monotherapy efficacy NE3107 Markedly Enhanced decreased survival of TH+ symptoms of neurons in the LID SNpc 4 SNpc, substan
Slide 6: Questions
Questions Marmoset PD study: poster #1353 Category: Parkinson’s Disease: Pharmacology and Therapy Exhibition Hall: August 30 (1-3 pm) Efficacy data from a phase 2 trial of NE3107 in patients with PD: poster #2 Category: Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia) Exhibi
Slide 7: References
References 1. Athauda D, Foltynie T. Insulin resistance and Parkinson’s disease: a new target for disease modification? Prog Neurobiol. 2016;145- 146:98-120. 2. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461-491. 3. Reading CL, Ahle
Slide 8: Acknowledgments and disclosures
Acknowledgments and disclosures Acknowledgments p-value communications provided editorial support, supported by BioVie Inc. Disclosures CA and CLR are employees of BioVie Inc. IHCHMP has nothing to disclose. 7